- Teva's Q2 2026 revenues fell 1% in U.S. dollars to $4.1 billion, affected by a 15% decrease in global generics revenues due to increased competition for lenalidomide capsules in the U.S.
- Revenues from Teva's key innovative brands—AUSTEDO, AJOVY, and UZEDY—grew 43% year-over-year in local currency terms to exceed $1 billion in Q2.
- Teva accelerated its neuroscience pipeline by completing the acquisition of Emalex Biosciences and its Tourette syndrome drug candidate, ecopipam, for approximately $700 million in cash.